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ARTICLE
Genome-wide homozygosity and multiple sclerosis in
Orkney and Shetland Islanders
Rebekah E McWhirter1, Ruth McQuillan1, Elizabeth Visser2, Carl Counsell2 and James F Wilson*,1
There is strong evidence for both genetic and environmental risk factors comprising the aetiology of multiple sclerosis (MS).
While much progress has been made in recent years in identifying common genetic variants using genome-wide association
studies, alternative approaches have remained relatively neglected. The prevalence of MS in Orkney and Shetland is among the
highest in the world. Previous studies have suggested that a higher degree of parental relatedness in these isolated communities
may contribute to the high rates of MS, indicating that recessive effects have an important role in MS aetiology. The Northern
Isles Multiple Sclerosis (NIMS) study investigated the potential role of genome-wide homozygosity in MS risk by genotyping 88
MS patients, 89 controls matched by age, sex and ancestry, and a further 89 controls matched for sex and ancestry, but passed
the majority of lifetime risk of developing MS (470 years of age). Three participants were removed on the basis of pedigree-
genomic anomalies (n¼263). Three measures of genome-wide homozygosity were generated for each individual, and association
with MS was assessed using logistic regression models. No effect of genome-wide homozygosity was detected, indicating that
inbreeding and consanguinity are not risk factors for MS in this population.
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INTRODUCTION
Multiple sclerosis (MS (MIM 1262000)) is an inflammatory auto-
immune disorder, with strong evidence for both genetic and environ-
mental risk factors in its aetiology. The importance of the major
histocompatibility complex (MHC) as a genetic risk locus has been
recognised for more than 30 years, and early linkage studies consis-
tently demonstrated the significance of the human leukocyte antigen
(HLA) class II locus.1–3 Fine-mapping and admixture studies suggest
the importance of theHLA-DRB1 gene, especially the HLA-DRB1*1501
allele in European populations, but complex interactions within the
MHC have further complicated interpretations of susceptibility.4–7 It is
only with the recent advances in genetic technology that influential loci
outside the MHC have begun to be identified, and considerable
progress has been made in recent years in identifying common variants
of modest effect using genome-wide association studies (GWAS).
However, these common variants account for only a portion of the
heritability of MS, and GWAS approaches are limited in their ability to
identify rare variants, epistatic effects or gene-environment interactions
that are likely to be important in explaining this missing heritability. To
date, alternative approaches have remained relatively neglected.
The prevalence of MS in Orkney and Shetland is among the highest
in the world, and accounting for the excess of MS in these isolated
island groups may help to elucidate MS aetiology.8 With relatively low
genetic and environmental variability, these populations are ideal for
studying genetic risk factors. Owing to the unusually high prevalence
of MS in the Orkney and Shetland Islands, the Northern Isles of
Scotland have long been of interest to MS researchers, and studies have
ranged across the gamut of environmental and genetic risk factors.9–20
Given the isolated location of these islands off the northern coast of
Scotland, and consequently the relatively minimal movement in and
out of the populations, several of these studies have examined the
potential effects of inbreeding and consanguinity within these popula-
tions as a means of indirectly assessing the role of recessive genetic
effects in MS.9,11,12 Using pedigree data for MS cases and controls in
Orkney, Roberts9 found 13% in each group to be the product of
consanguineous unions. However, the inbreeding coefficients (the
probability that two alleles at a random locus are identical-by-descent,
having been inherited from a common ancestor) were twice as high in
cases (F¼0.00364) as in controls (F¼0.00170). Similarly, kinship
coefficients (the probability that an allele at a random locus is identical
in two individuals) between parents of cases were twice that of parents
of controls (j¼364105 compared with j¼170105). Despite the
small size of this study sample, these results indicate a potential role
for recessive alleles inherited identical-by-descent from both parents in
influencing MS risk. A study in Shetland found similar, albeit less
marked, differences in that population.11
Further evidence for a recessive effect in MS has been found
elsewhere. A study in a Dutch isolate found MS patients to be
significantly more related to each other than the control group, and
more often inbred (82% compared with 36%).21 Sadovnick et al22
found the sibling recurrence rate of MS to be almost four times as high
among offspring of consanguineous parents than among those of
unrelated parents (8.0% compared with 2.3%). Evidence for the
importance of a founder effect in explaining the high prevalence of
MS in the Southern Ostrobothnian region of western Finland has been
found, which is also consistent with a possible role of recessive effects
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in MS aetiology.23 Callander and Landtblom24 reported a cluster of
MS cases in Lysvik in the Swedish county of Va¨rmland occurring in a
family with documented marriages between cousins, increasing the
opportunity for recessive effects to influence MS risk.
Amidst the recent enthusiasm for GWAS in risk allele identification,
the potential of homozygosity studies for identifying recessive effects
has been relatively neglected in MS, as in other diseases. Genetic
isolates, such as Orkney and Shetland, are ideal for investigating
various aspects of homozygosity in disease aetiology, an approach
which has been very successful at finding recessive effects in Mendelian
diseases and which is increasingly being used for complex diseases.25–27
Although earlier methods of estimating homozygosity relied on either
single-point or complex multi-point inferences from limited marker
data, McQuillan28,29 recently developed a more robust observational
method that exploits the availability of high-density single nucleotide
polymorphism (SNP) data. Such high-density data can be used to
describe both ancient and more recent parental relatedness through
comparing the total proportion of homozygosity and unbroken runs
of homozygous markers in study participants. The application of this
more accurate measure of homozygosity to a population possibly
enriched for MS-associated alleles, such as those of the Northern Isles,
has the potential to expose further evidence of the recessive effects
indicated by earlier studies, and presents a complementary strategy to
GWAS in the description of the genetic architecture of MS. This study
aims to investigate the cumulative impact of (semi-)recessive effects
on MS risk using a variety of measures of genome-wide homozygosity.
MATERIALS AND METHODS
Study participants
The Northern Isles Multiple Sclerosis (NIMS) study recruited MS patients and
unaffected controls from the Orkney and Shetland Islands under approval from
the North of Scotland Research Ethics Committee. A total of 266 individuals
were recruited, of whom 88 were cases, 89 age-matched controls and 89 elderly
controls. All known patients with MS living on the islands or in the Grampian
or Highland regions of mainland Scotland were identified by contacting general
practices on the islands, and reviewing MS databases held in secondary care in
Aberdeen, Inverness, Orkney and Shetland. Recruitment of cases to the study
was conducted through letters forwarded by general practitioners inviting those
of Orcadian or Shetlandic descent to participate. Some cases volunteered
directly, following media coverage.
Two groups of controls were recruited: one matched with cases by age,
sex and ancestry within the islands; the other matched by sex and ancestry
within the islands, but passed the majority of lifetime risk of developing
MS. Ancestry was considered an important factor to control for, in order to
account for the fine-scale population genetic structure that has developed
between parishes and isles as a result of the very short distances over which
marriages were traditionally conducted in these isolated islands. Both groups
were recruited from among volunteers who came forward after requests
in the local media for general controls and for those born between 1935
and 1937. NHS Shetland also assisted by forwarding invites to a random
selection of their patients born between 1935 and 1937. These years were
selected on the basis that evidence indicates that the risk of developing MS is
lower after the age of 70, and that it is difficult to reliably construct complete six
generation pedigrees in all ascendant lineages for people born before c.1930.28
Controls with first or second degree relatives with MS, or those who screened
positive for possible undiagnosed MS, were excluded and a new control was
chosen.
Informed consent was obtained from all participants. A neurology clinical
research fellow (EV) then performed a structured history and examination
(including the Kurtzke Expanded Disability Score) of all patients and controls
and reviewed their hospital and GP notes.30 The Poser and McDonald
diagnostic criteria for MS were then applied and the type of MS classified.31–33
Blood samples were subsequently collected and detailed family history ques-
tionnaires administered.
Genotyping
Genomic DNA was extracted from whole blood for MS cases and controls.
Samples were genotyped using the Illumina Infinium HumanOmni1 – Quad
BeadChip (Illumina Inc., San Diego, CA, USA), according to the manufac-
turer’s protocols, involving 1 140 419 markers and coded according to the top
strand allele coding scheme.
Data analysis
Data cleaning and quality control were performed on the genotyping data using
PLINK version 1.04, and SNPs with low genotyping call rates (o0.95,
n¼35 241), low minor allele frequency (o0.01, n¼231 500) and Hardy–
Weinberg equilibrium failures (Po0.001, n¼2845) were removed.34 Individuals
with low genotyping calls were checked for, but none required removal (o0.97,
n¼0). X chromosomes display different levels of homozygosity to autosomes
(and are hemizygous in males), and their inclusion in an analysis of this type
would give misleading results. For this reason, non-autosomal SNPs were also
removed (n¼19 176), resulting in a total of 266 individuals and 794 367 SNPs.
The genotyping rate per individual is 0.999032. The length of typed autosomal
genome, excluding centromeres is 2 689 340 kb and the density of SNP coverage
is 3.38 kb/SNP.
Reported and genomic sex were compared and no anomalies were identified,
resulting in no removals. Pedigree-genomic anomalies were also assessed,
indicating the removal of three individuals: one on the basis of sample
contamination and two on the basis of inconsistency between genomic and
pedigree information suggestive of DNA switching or other errors. Multi-
dimensional scaling plots of identity-by-state sharing distances revealed no
extreme outliers, but identified three principal components to be included in
subsequent regression analyses. The data set was pruned for strong local LD,
and the resultant set contains 41 004 SNPs, a typed autosomal genome length of
2672.78Mb and a SNP coverage density of 65.18 kb/SNP.
Three measures of genome-wide homozygosity were generated in PLINK for
each individual.34 These included the following:
(1) Hobs: observed homozygosity is the simplest measure. It is defined as the
percentage of SNPs that are homozygous, and estimates total parental
relatedness; that is, this measure reflects the size of both an individual’s
ancient as well as recent ancestral genepool.
(2) FROH: the proportion of the typed autosomal genome in runs of
homozygosity longer than 1Mb, as a measure of recent ancestral
history.29
(3) FROH(pr): a similar measure to FROH, but is a more stringent method of
assessing recent parental relatedness, as it utilises a panel of independent
SNPs (after LD pruning).
Using R version 2.10.1,35 these measures were included in logistic regression
analyses of cases and age-matched controls, and of cases and 1936 controls,
adjusting for sex and the three principal components identified in the
multidimensional scaling plots.
RESULTS
Demographic characteristics for the final 263 participants are
summarised in Table 1. The three measures of homozygosity gener-
ated (FROH, FROH_pr and Hobs) are summarised in Table 2. To
minimise the potential confounding influence of differential numbers
of half-Orcadian and half-Shetlandic participants (that is, those with
one set of grandparents born outside the Northern Isles – a group with
significantly lower levels of homozygosity than other subjects), figures
are given for both the whole sample and for a sample restricted to
those with all four grandparents born in the Northern Isles. In his
study of inbreeding and MS, Roberts further divided his sample into
those with all four grandparents born in either Orkney or Shetland.9
To facilitate comparison with Roberts’ work, analogous summaries are
given in Table 3.
None of these measures of homozygosity was found to be positively
associated with MS in any of the samples (Table 4). In fact, within the
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cases and past lifetime risk control group, there was marginal evidence
of a negative association between genome-wide homozygosity and
MS. The effects are mostly in the opposite direction to that indicated
by previous research, although this trend is reversed when only those
with Shetland-born grandparents are examined. Given the very small
subsample and consequently wide confidence intervals, the impor-
tance of this finding is questionable.
DISCUSSION
The small population and historically limited migration into the
Northern Isles mean that these populations experience higher levels
of parental relatedness than elsewhere in the British Isles, leading to a
greater proportion of alleles at a given locus in an individual being
identical-by-descent.36 It could reasonably be expected that if recessive
effects were an important part of MS aetiology, they could easily be
discerned in such a population enriched for homozygosity. This,
combined with rates of MS among the highest in the world, makes
the populations of Orkney and Shetland ideal for investigating the
effect of genome-wide homozygosity on MS risk.
That runs of homozygosity increase with endogamous matings is
demonstrated by the consistently higher mean values of FROH and
FROH_pr in participants with four Northern Isles grandparents com-
pared with the whole sample. Mean Hobs values are also higher in the
endogamous group, but to a lesser extent, as this measure also
includes more ancient shared parental ancestry common in all
participants. Participants in the past lifetime risk control group,
being older, are more likely to have four grandparents born in the
Northern Isles (or within one isle or parish), and consequently
exhibited higher mean FROH, FROH_pr and Hobs values than either
cases or age-matched controls. It is this differential indigenousness
that biases the results to produce the apparent protective effect of
homozygosity against MS when cases are compared with the past
lifetime risk control group, rather than any real effect.
Overall, no effect of genome-wide homozygosity was detected.
Although this does not discount the possibility of recessive effects,
particularly for individual rare recessive variants, it does suggest a
limit to the size of any genome-wide effect, if the failure to detect it is a
consequence of inadequate sample size. Further, it places some doubt
upon the value of Roberts’ extrapolation of the potential involvement
of recessive effects from cruder measures.9 It is worth noting that,
before that study, Roberts, Roberts and Poskanzer12 found no associa-
tion between inbreeding or kinship coefficients and disease status, and
it was only when Roberts expanded upon this study to include a larger
number of participants that an effect was found. This might suggest
that the present study has failed to detect a real effect through
small numbers. However, Roberts used a total of 69 cases, with
corresponding controls, and a pedigree-based measure of inbreeding,
which owing to its incomplete and error-prone nature, can provide
Table 1 Demographic characteristics of cases, age-matched controls
and past lifetime risk controls
Characteristic Cases (%)
Age-matched
controls (%)
1936 Controls
(%)
Number 88 88 87
Sex
Female 64 (72.7) 62 (70.5) 61 (70.1)
Male 24 (27.3) 26 (29.5) 26 (29.9)
Female:male ratio 2.67:1 2.34:1 2.35:1
Place of residence
Orkney 37 (42) 54 (61) 55 (63)
Shetland 21 (24) 29 (33) 30 (34)
Grampian 16 (18) 4 (5) 0 (0)
Highland 7 (8) 0 (0) 1 (1)
Lothian 4 (5) 1 (1) 1 (1)
Fife 1 (1) 0 (0) 0 (0)
Strathclyde 1 (1) 0 (0) 0 (0)
USA 1 (1) 0 (0) 0 (0)
Age (years)
Age at onset of disease
Mean (n¼87) 32
Range 8–63
Age at diagnosis
Mean (n¼85) 40
Range 8–76
Age at time of interview
Mean 50.7 50 72.8
Range 27.4–77.0 26.9–76.7 70.1–89.2
Disease course
Relapsing-remitting type 35 (39.8)
Secondary progressive –
with relapses
26 (29.5)
Secondary progressive –
without relapses
15 (17.0)
Primary progressive 12 (13.6)
Clinically isolated syndrome 0 (0)
Expanded disability status score
o3 27 (30.7)
3–o6 12 (13.6)
6–o7 29 (33.0)
Z7 20 (22.7)
Table 2 Means (%) and SD for three measures of homozygosity by MS status in all participants and in those with four grandparents born in
Orkney or Shetland
Whole sample Four Northern Isles grandparents
Measure of
Homozygosity
Cases
(n¼88)
Age-matched
controls (n¼88)
Past lifetime risk
controls (n¼87)
Cases
(n¼52)
Age matched
controls (n¼53)
Past lifetime risk
controls (n¼62)
FROH 1.59 (0.57) 1.67 (0.76) 1.90 (1.13) 1.69 (0.64) 1.84 (0.90) 2.09 (1.26)
FROH_pr 0.37 (0.26) 0.41 (0.30) 0.54 (0.48) 0.43 (0.31) 0.46 (0.34) 0.62 (0.54)
Hobs 67.88 (0.30) 67.89 (0.30) 67.93 (0.30) 67.95 (0.31) 67.96 (0.34) 67.99 (0.48)
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only expected, rather than realised, levels of homozygosity.9 Conver-
sely, this study included a total of 88 cases, with two sets of
corresponding controls, and a more accurate, genomic measure of
realised homozygosity. The number of cases was, necessarily, reduced
when only those with all four grandparents born in Orkney or
Shetland were retained (n¼52), but the increased precision of the
more direct measure of homozygosity should have enabled replication
of Roberts’ earlier result, if present.
Standard regression techniques assume independent observations
but, as the sample includes related individuals, this assumption is
potentially violated. Although this suggests that a regression model
accounting for relatedness may be indicated, it is salient to note that
the sample is not highly related (mean pair-wise kinship: pi
hat¼0.004), nor is MS highly heritable. Thus, standard logistic
regression techniques are appropriate for use in this instance.
The poor levels of precision indicated by the wide confidence
intervals are the result of the relatively small sample size. This is an
unavoidable consequence of restricting the scope of the study to the
small populations of Orkney and Shetland, as there are only a limited
number of MS cases available for recruitment. Furthermore, the
limited number of cases precludes use of this data set as a stand-
alone GWAS, although the data may be included as part of a meta-
analysis. Despite this, the use of genetic isolates to investigate the
genetic risk factors of complex diseases provides a unique opportunity
to elucidate the causative role of recessive and rare variants. While the
findings of such investigations may be less widely generalisable than
those of GWAS, they nevertheless contribute to greater understanding
of the aetiology of disease and, furthermore, are of particular relevance
to the study population.
No effect of genome-wide homozygosity was observed, and there-
fore provides no evidence that inbreeding or consanguinity is a risk
factor for MS in these populations. However, recessive effects at
individual variants may still prove important in explaining the high
rates of MS in this population. Techniques for performing homo-
zygosity mapping have recently been developed for use beyond the
previously limited scope of consanguineous families, and this repre-
sents the logical next step in assessing how homozygosity and recessive
alleles might contribute to the heritable risk of developing MS.37
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGEMENTS
We would like to thank the people of Orkney and Shetland who kindly
participated in this study. We are also grateful to Dr Sarah Taylor, Dr Marthinus
Roos and the general practices of Orkney and Shetland, for assistance in
recruiting participants; Kay Lindsay and Susan Hermiston, for project
management and administration; Jo Graham, for meticulous work in tracing
the pedigrees of study participants; Mirna Kirin, for invaluable statistical
advice; Gisela Barr, for data entry, and Lesley McGoohan, for database work.
DNA extraction was performed at the Wellcome Trust Clinical Research Facility
at the Western General Hospital, Edinburgh, and genotyping was performed at
GeneProbe (Tepnel), Livingston, West Lothian. This work was supported by the
MS Society UK, the Volant Trust and Royal Society.
1 Sawcer S, Ban M, Maranian M et al: A high-density screen for linkage in multiple
sclerosis. Am J Hum Genet 2005; 77: 454–467.
2 Olerup O, Hillert J: HLA class II-associated genetic susceptibility in multiple sclerosis:
a critical evaluation. Tissue Antigens 1991; 38: 1–15.
3 Naito S, Namerow N, Mickey MR, Terasaki PI: Multiple sclerosis: association with
HL-A3. Tissue Antigens 1972; 2: 1–4.
4 Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL: The genetics of multiple sclerosis:
SNPs to pathways to pathogenesis. Nat Rev Genet 2008; 9: 516–526.
Table 3 Means (%) and SD for three measures of homozygosity by MS status in participants with all four grandparents born in the Orkney
Islands, and in those with four grandparents born in the Shetland Islands
Four Orkney grandparents Four Shetland grandparents
Measure of
homozygosity
Cases
(n¼37)
Age-matched
controls (n¼34)
Past lifetime risk
controls (n¼38)
Cases
(n¼12)
Age-matched
controls (n¼17)
Past lifetime risk
controls (n¼23)
FROH 1.63 (0.47) 1.84 (0.99) 2.07 (1.20) 1.99 (1.00) 1.85 (0.75) 2.15 (1.40)
FROH_pr 0.38 (0.28) 0.45 (0.36) 0.61 (0.53) 0.61 (0.36) 0.45 (0.31) 0.65 (0.58)
Hobs 67.91 (0.26) 67.97 (0.36) 68.01 (0.50) 68.08 (0.44) 67.91 (0.30) 67.97 (0.45)
Table 4 Association between genome-wide homozygosity and MS
susceptibility
Group Measure OR CI P-value
Age matched (full sample) FROH 0.85 0.54, 1.35 0.500
FROH_pr 0.60 0.21, 1.76 0.355
Hobs 0.88 0.32, 2.43 0.800
Past lifetime risk (full sample) FROH 0.65 0.44, 0.97 0.034
FROH_pr 0.26 0.09, 0.72 0.009
Hobs 0.72 0.32, 1.64 0.438
Age matched
(four NI grandparents)
FROH 0.80 0.47, 1.37 0.416
FROH_pr 0.77 0.22, 2.64 0.675
Hobs 0.97 0.28, 3.38 0.962
Past lifetime risk
(four NI grandparents)
FROH 0.64 0.41, 1.00 0.051
FROH_pr 0.30 0.10, 0.89 0.030
Hobs 0.75 0.29, 1.89 0.536
Age matched
(four Orkney grandparents)
FROH 0.78 0.38, 1.63 0.512
FROH_pr 0.61 0.13, 2.91 0.535
Hobs 0.57 0.10, 3.21 0.526
Past lifetime risk
(four Orkney grandparents)
FROH 0.56 0.29, 1.09 0.089
FROH_pr 0.18 0.03, 0.99 0.049
Hobs 0.56 0.53, 1.88 0.345
Age matched
(four Shetland grandparents)
FROH 1.26 0.48, 3.29 0.635
FROH_pr 4.16 0.25, 68.39 0.319
Hobs 3.18 0.28, 35.60 0.349
Past lifetime risk
(four Shetland grandparents)
FROH 0.89 0.42, 1.88 0.765
FROH_pr 0.61 0.10, 3.90 0.605
Hobs 1.73 0.27, 10.95 0.559
Abbreviation: NI, Northern Isles of Scotland.
Genome-wide homozygosity and multiple sclerosis
RE McWhirter et al
201
European Journal of Human Genetics
5 Oksenberg JR, Barcellos LF, Cree BAC et al: Mapping multiple sclerosis susceptibility
to the HLA-DR locus in African-Americans. Am J Hum Genet 2004; 74: 160–167.
6 Reich D, Patterson N, De Jager PL et al: A whole-genome admixture scan finds a
candidate locus for multiple sclerosis susceptibility. Nat Genet 2005; 37: 1113.
7 Chao MJ, Barnardo MCNM, Lincoln MR et al: HLA class I alleles tag HLA-DRB1*1501
haplotypes for differential risk in multiple sclerosis susceptibility. Proc Natl Acad Sci
USA 2008; 105: 13069–13074.
8 Rosati G: The prevalence of multiple sclerosis in the world: an update. Neurol Sci
2001; 22: 117–139.
9 Roberts DF: Consanguinity and multiple sclerosis in Orkney. Genet Epidemiol 1991; 8:
147–151.
10 Roberts DF, Papiha SS, Poskanzer DC: Polymorphisms and multiple sclerosis in
Orkney. J Epidemiol Commun H 1979; 33: 236–242.
11 Roberts DF, Roberts MJ, Poskanzer DC: Genetic analysis of multiple sclerosis in
Shetland. J Epidemiol Commun H 1983; 37: 281–285.
12 Roberts DF, Roberts MJ, Poskanzer DC: Genetic analysis of multiple sclerosis in
Orkney. Br Med J 1979; 33: 229–235.
13 Dean G, Goodall J, Downie A: The prevalence of multiple sclerosis in the Outer
Hebrides compared with north-east Scotland and the Orkney and Shetland Islands. J
Epidemiol Commun H 1981; 35: 110–113.
14 Poskanzer D, Terasaki PI, Prenney LB, Sheridan JL, Park MS: Multiple sclerosis in
the Orkney and Shetland Islands III: histocompatibility determinants. J Epidemiol
Commun H 1980; 34: 253–257.
15 Poskanzer DC, Prenney LB, Sheridan JL, Kondy JY: Multiple sclerosis in the Orkney and
Shetland Islands. I: epidemiology, clinical factors, and methodology. J Epidemiol
Commun H 1980; 34: 229–239.
16 Poskanzer DC, Sever JL, Sheridan JL, Prenney LB: Multiple sclerosis in the Orkney and
Shetland Islands. IV: viral antibody titres and viral infections. J Epidemiol Commun
H 1980; 34: 258–264.
17 Poskanzer DC, Sever JL, Terasaki PI, Prenney LB, Sheridan JL, Park MS: Multiple
sclerosis in the Orkney and Shetland Islands. V: the effect on viral titres of histocom-
patibility determinants. J Epidemiol Commun H 1980; 34: 265–270.
18 Poskanzer DC, Sheridan JL, Prenney LB, Walker AM: Multiple sclerosis in the Orkney
and Shetland Islands. II: the search for an exogenous aetiology. J Epidemiol Commun H
1980; 34: 240–252.
19 Poskanzer DC, Walker AM, Yonkondy J, Sheridan JL: Studies in the epidemiology
of multiple sclerosis in the Orkney and Shetland Islands. Neurology 1976; 26: 14–17.
20 Taylor R, Illsley R, Poskanzer DC: Multiple sclerosis in the Orkney and Shetland
Islands. VI: the effects of migration and social structure. J Epidemiol Commun H 1980;
34: 271–276.
21 Hoppenbrouwers IA, Pardo Cortes LM, Aulchenko YS et al: Familial clustering of
multiple sclerosis in a Dutch genetic isolate. Mult Scler 2007; 13: 17–24.
22 Sadovnick AD, Yee IML, Ebers GC: Recurrence risks to sibs of MS index cases: impact
of consanguineous matings. Neurology 2001; 56: 784–785.
23 Tienari PJ, Sumelahti M-L, Rantama¨ki T, Wikstro¨m J: Multiple sclerosis in western
Finland: evidence for a founder effect. Clin Neurol Neurosurg 2004; 106: 175–179.
24 Callander M, Landtblom A-M: A cluster of multiple sclerosis in Lysvik in the Swedish
county of Va¨rmland. Acta Neurol Scand 2004; 110: 14–22.
25 Botstein D, Risch N: Discovering genotypes underlying human phenotypes: past
successes for mendelian disease, future approaches for complex disease. Nat Genet
2003; 33: 228–237.
26 Van Duijn CM, Dekker MCJ, Bonifati V et al: PARK7, a novel locus for autosomal
recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 2001;
69: 629–634.
27 Ewald H, Wikman FP, Teruel BM et al: A genome-wide search for risk genes using
homozygosity mapping and microarrays with 1,494 single-nucleotide polymorphisms
in 22 eastern Cuban families with bipolar disorder. Am J Med Genet B 2004; 133:
25–30.
28 McQuillan R: Homozygosity, Inbreeding and Health in European Populations, PhD
thesis, University of Edinburgh, Edinburgh, UK, 2009.
29 McQuillan R, Leutenegger AL, Abdel-Rahman R et al: Runs of homozygosity in
European populations. Am J Hum Genet 2008; 83: 359–372.
30 Kurtzke JF: Rating neurologic impairment in multiple sclerosis; an expanded disability
status scale (EDSS). Neurology 1983; 33: 1445–1452.
31 Poser CM, Paty DW, Scheinberg L et al: New diagnostic criteria for multiple sclerosis:
guidelines for research protocols. Ann Neurol 1983; 13: 227–231.
32 McDonald WI, Compston A, Edan G et al: Recommended diagnostic criteria for
multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple
sclerosis. Ann Neurol 2001; 50: 121–127.
33 Polman CH, Reingold SC, Edan G et al: Diagnostic criteria for multiple sclerosis: 2005
revisions to the ‘McDonald Criteria’. Ann Neurol 2005; 58: 840–846.
34 Purcell S, Neale B, Todd-Brown K et al: PLINK: a toolset for whole-genome association
and population-based linkage analysis. Am J Hum Genet 2007; 81: 559–575.
35 R Development Core Team: R: A language and environment for statistical computing.
R Foundation for Statistical Computing, Vienna, Austria, 2008. http://www.R-project.org.
36 Roberts DF: Report on the Genetic Analysis of Multiple Sclerosis in the Orkney and
Shetland Islands. National Institutes of Health, 1979.
37 Hildebrandt F, Heeringa SF, Ru¨schendorf F et al: A systematic approach to mapping
recessive disease genes in individuals from outbred populations. PLoS Genet 2009; 5:
e1000353.
Genome-wide homozygosity and multiple sclerosis
RE McWhirter et al
202
European Journal of Human Genetics
